Objective:To study the effect of recombinant human erythropoietin (rHu-EPO) therapy on convalescent serological indicators in patients with severe craniocerebral injury.Methods:Patients with severe craniocerebral inju...Objective:To study the effect of recombinant human erythropoietin (rHu-EPO) therapy on convalescent serological indicators in patients with severe craniocerebral injury.Methods:Patients with severe craniocerebral injury who were treated in Fifth Hospital in Wuhan between July 2014 and February 2017 were selected and randomly divided into the rHu-EPO group who accepted rHu-EPO combined with conventional therapy and the control group who accepted conventional therapy. Before and after treatment, serum levels of nerve injury indexes, inflammation indexes, oxidative stress indexes and apoptosis indexes were measured. Results:Serum Tau, S100B, GFAP, NSE, IL-1β, TNF-α, VCAM-1, ICAM-1, LPO, AOPP, 8-iso-PGF2 , sTRAIL, sFas and sFasL levels of both groups of patients 14 d after treatment were significantly lower than those before treatment, and serum Tau, S100B, GFAP, NSE, IL-1β, TNF-α, VCAM-1, ICAM-1, LPO, AOPP, 8-iso-PGF2 , sTRAIL, sFas and sFasL levels of rHu-EPO group were significantly lower than those of control group.Conclusion: rHu-EPO therapy can significantly improve the convalescent nerve injury, inflammation, oxidative stress and apoptosis in patients with severe craniocerebral injury.展开更多
文摘Objective:To study the effect of recombinant human erythropoietin (rHu-EPO) therapy on convalescent serological indicators in patients with severe craniocerebral injury.Methods:Patients with severe craniocerebral injury who were treated in Fifth Hospital in Wuhan between July 2014 and February 2017 were selected and randomly divided into the rHu-EPO group who accepted rHu-EPO combined with conventional therapy and the control group who accepted conventional therapy. Before and after treatment, serum levels of nerve injury indexes, inflammation indexes, oxidative stress indexes and apoptosis indexes were measured. Results:Serum Tau, S100B, GFAP, NSE, IL-1β, TNF-α, VCAM-1, ICAM-1, LPO, AOPP, 8-iso-PGF2 , sTRAIL, sFas and sFasL levels of both groups of patients 14 d after treatment were significantly lower than those before treatment, and serum Tau, S100B, GFAP, NSE, IL-1β, TNF-α, VCAM-1, ICAM-1, LPO, AOPP, 8-iso-PGF2 , sTRAIL, sFas and sFasL levels of rHu-EPO group were significantly lower than those of control group.Conclusion: rHu-EPO therapy can significantly improve the convalescent nerve injury, inflammation, oxidative stress and apoptosis in patients with severe craniocerebral injury.
